This medication is used for managing underlying lipid metabolism disorders, including primary hypercholesterolemia and mixed dyslipidemia, which are conditions marked by symptoms related to systemic imbalance of fatty substances. The drug is relevant for supporting the reduction of cardiovascular risk factors and may be part of symptomatic management applied in addressing high cardiovascular risk. This includes patients with established Coronary Heart Disease (CHD), those following an Acute Coronary Syndrome (ACS), and individuals with severe inherited conditions like Familial Hypercholesterolemia. The therapeutic benefit is supporting the lowering of harmful lipids, specifically Low-Density Lipoprotein Cholesterol ( LDL-C) and Total Cholesterol, which contributes to supporting a more stable lipid profile. The drug is often relevant in clinical scenarios where the severity of cholesterol elevation is pronounced or when maximal statin monotherapy is considered insufficient.

“The medication is commonly applied when supportive symptom management is appropriate for severely elevated cholesterol levels.”

---

Quick Fact: Focus on Systemic Imbalance

Property	Description
Primary Indication Focus	Primary Hypercholesterolemia, Mixed Dyslipidemia
Key Therapeutic Benefit	Supports reduction of LDL-C and Total Cholesterol
Relevant Clinical Context	High Cardiovascular Risk State (e.g., post-ACS)
Use Classification	Adjunctive therapy when statin alone is insufficient

Eligibility for Инеджи (Ezetimibe and Simvastatin)

Official regulatory information strictly defines the patient populations permitted to use this medicine and those for whom use is prohibited or restricted. The drug is contraindicated and must not be used by patients with:

• Known hypersensitivity or allergy to ezetimibe, simvastatin, or any components of the tablet.
• Active liver disease or unexplained, persistent elevations of liver enzymes.
• Women who are pregnant or may become pregnant, or those who are breastfeeding.
• Patients concomitantly taking certain medications, including strong CYP3A4 inhibitors (e.g., specific antifungals, HIV protease inhibitors, nefazodone, cobicistat), as well as gemfibrozil, cyclosporine, danazol, or fusidic acid.

---

Restrictions and Exclusions

Use is not recommended for children under 10 years of age due to insufficient safety and efficacy data. Patients with moderate or severe hepatic impairment (liver dysfunction) should not use this medicine. For patients with severe renal impairment, doses exceeding 10 mg/20 mg daily are generally to be used with caution and close monitoring. The 10 mg/80 mg dose is restricted to adult patients who have taken it chronically (e.g., 12 months or more) without developing muscle toxicity.

The officially documented interaction profile for Инеджи (Ezetimibe/Simvastatin) is structured by formal restrictions, timing requirements, and warnings concerning specific substance categories.

Contraindicated Combinations

Co-administration is strictly contraindicated with certain substances due to the risk of significant increases in the Simvastatin component's systemic exposure. This includes strong CYP3A4 inhibitors (e.g., Itraconazole, Erythromycin, HIV protease inhibitors, Cobicistat-containing products), as well as Cyclosporine, Danazol, and Gemfibrozil.

Pharmacokinetic and Pharmacodynamic Interactions

The Simvastatin component is a substrate for the CYP3A4 enzyme and the OATP1B1 uptake transporter, which are key targets for documented pharmacokinetic interactions. Separately, a pharmacodynamic interaction exists with lipid-modifying doses of Niacin (nicotinic acid ge 1 g/day) and fibrates (excluding Gemfibrozil), which carries a documented additive risk of myopathy.

Interaction Type	Examples of Agents	Required Action/Restriction
Exposure Modifying	Amiodarone, Diltiazem, Verapamil	Maximum Simvastatin dose must be limited
Timing Separation	Bile Acid Sequestrants (e.g., Cholestyramine)	Must be administered mathbf2 hours before or mathbf4 hours after Инеджи

Consumption of large quantities of grapefruit juice must be avoided as it inhibits CYP3A4, increasing Simvastatin plasma concentrations. When co-administered with Coumarin anticoagulants (e.g., Warfarin), regular monitoring of the International Normalized Ratio (INR) is required upon initiation or dose change.

Инеджи employs a dual-mechanism approach to modulate cholesterol homeostasis by intervening at two crucial points: the body's internal production and its absorption of external cholesterol.

Simvastatin's primary action is the competitive inhibition of the HMG-CoA Reductase enzyme in the liver, suppressing the mevalonate pathway. This molecular deficit triggers a feedback loop, causing the liver to increase the surface expression of its LDL Receptors, which facilitate the removal of Low-Density Lipoprotein Cholesterol (LDL-C) from the bloodstream.

Ezetimibe provides a complementary domain by focusing on the Niemann-Pick C1-Like 1 (NPC1L1) protein on the intestinal wall. The selective blockade of this transporter prevents dietary and biliary cholesterol from being absorbed, resulting in a reduction in the overall cholesterol load delivered to the liver and contributing to the reduction in circulating LDL-C.

The core mechanistic factor is the synergy achieved when both pathways are simultaneously interrupted. This combined action mitigates the body's natural compensatory response—which would typically increase absorption when synthesis is inhibited—due to the complementary interruption of two separate homeostatic pathways.

The drug Инеджи (ezetimibe/simvastatin) is supplied as a Fixed-Dose Combination (FDC) tablet for oral administration. The official administration protocol defines specific dose limits, timing, and population-specific considerations.

Dosing and Frequency

The medicine is taken as a single dose once daily in the evening, and it may be taken with or without food. Standard available strengths are 10/10 mg, 10/20 mg, 10/40 mg, and 10/80 mg. The usual recommended starting dose is 10/10 mg/day or 10/20 mg/day. The maximum recommended dose for general use is 10/40 mg/day. The 10/80 mg/day strength is restricted to patients who have tolerated it chronically (e.g., ge 12 months) and is prohibited for initiating new patients or for routine dose titration.

Administration Guidelines

Official guidelines state that the tablets should not be divided. If a dose is missed, the instruction is to take the dose as soon as remembered, but not to double the next dose. Dosing adjustments are typically assessed 2 or more weeks following initiation or dose change, based on lipid level analysis.

Special administration rules apply for certain patient groups and concomitant treatments:

• Pediatric Use: For children aged ge 10 years (with Heterozygous Familial Hypercholesterolemia), the dosage range extends up to 10/40 mg/day.
• Renal Impairment: Doses exceeding 10/20 mg/day should be used with caution and close monitoring in patients with moderate to severe renal impairment.
• Hepatic Impairment: Use is not recommended for those with moderate to severe hepatic impairment.
• Bile Acid Sequestrants: If administered with a bile acid sequestrant (like cholestyramine), the Инеджи tablet must be taken ge 2 hours before or ge 4 hours after the sequestrant to avoid interference with absorption.

Research evidence / Overview of studies for Инеджи

The clinical evaluation of the ezetimibe/simvastatin combination (Инеджи) is based on formal studies, including randomized controlled trials (RCTs), that was evaluated in high-risk groups. This overview describes the research landscape, what the studies monitored, and the areas where data remains limited.

---

Evidence for Management of Primary Hypercholesterolemia

Research examined individuals with primary hypercholesterolemia using short- and intermediate-term randomized controlled trials. These studies was studied for outcomes related to systemic or functional imbalance, such as Low-Density Lipoprotein Cholesterol ( LDL-C) and Total Cholesterol. The trials compared the observed measurements from the combination therapy group against monotherapy with a statin (simvastatin) alone.

Findings describe patterns observed in the studies where the combination group reported measurements of LDL-C change compared to the group receiving statin monotherapy alone. Studies also reported that a higher percentage of subjects in the combination group demonstrated measurements at specific cholesterol thresholds during the observation period. Long-term clinical event outcomes are not characterized by the short-term biomarker studies.

---

Evidence for Major Cardiovascular Event Reduction in High-Risk Patients

A landmark, long-term randomized controlled trial was used in research exploring how symptoms change over time, focusing on individuals who had recently experienced an Acute Coronary Syndrome (ACS). This research examined outcomes related to systemic or functional imbalance, specifically a composite of major events, including heart attack and stroke. The study monitored these clinical events over a median period of six years.

The main trial data show patterns related to the group receiving the combination therapy reported fewer occurrences of the composite major cardiovascular event endpoint compared to the group receiving simvastatin alone. Research also explored subgroups, and findings suggest that patients who also had diabetes was associated with patterns describing a difference in event occurrence.

---

Areas of Research Uncertainty and Study Limitations

Research exploring long-term clinical outcomes is ongoing or limited in specific subgroups. The evidence regarding changes measured during the study period for surrogate markers, such as artery wall thickness, findings were mixed and may require further research. The comparative evidence is lacking in scenarios such as the Chronic Kidney Disease (CKD) trial, where the design did not permit how to isolate the specific contribution of each ingredient to the reported patterns.

Key Studies & References

1. A-to-Z list of FDA Drugs: Simvastatin

Common questions about Инеджи (FAQ)

Q: Why is Инеджи sometimes prescribed for this condition?

A: According to the official product information, the medicine is indicated as an addition to diet to help reduce elevated levels of total cholesterol, LDL-C (often called 'bad cholesterol'), and other fats in the blood. It is prescribed for patients who have primary hyperlipidemia, which includes specific types of familial high cholesterol.

Q: How quickly should I expect to see any effects after starting Инеджи?

A: Based on the regulatory information for the simvastatin component, the greatest reduction in LDL-C is typically observed after about four weeks of starting therapy. Monitoring of cholesterol levels (blood fats) is typically assessed approximately 4 to 12 weeks following the initiation or dosage adjustment, as described in regulatory documentation.

Q: Can Инеджи affect my sleep schedule or energy levels?

A: Official reports mention fatigue, or feeling tired, as an adverse reaction observed in clinical trials for the ezetimibe component. Additionally, post-marketing experience reports have included nervous system disorders such as depression and headache.

Q: What are the most commonly reported side effects of Инеджи?

A: Common adverse reactions reported in clinical trials include headache, muscle pain (myalgia), upper respiratory tract infection, and diarrhea. Official documents also note that increases in a liver enzyme called ALT have been observed.

Q: Are there any common foods or drinks that should be avoided while using Инеджи?

A: Yes, official drug information advises against consuming large quantities of grapefruit juice, specifically more than one quart daily. This precaution is advised because high consumption of grapefruit juice can potentially increase the risk of serious muscle problems associated with the simvastatin component.

Q: Is Инеджи safe to use if I am also taking vitamins or herbal supplements?

A: Official drug labels list many specific drug-drug and drug-herb interactions that must be considered. Regulatory documents state that all prescription and non-prescription medicines, vitamins, herbal products, and supplements should be discussed with a healthcare provider.

Q: How does the medicine change what happens in the body?

A: The medicine is a fixed-dose combination of two active ingredients that work in two different ways. Ezetimibe works by inhibiting the absorption of cholesterol in the small intestine. Simvastatin works by reducing the production of cholesterol in the liver.

Q: What are the long-term research findings about using Инеджи?

A: Clinical studies, including long-term trials, have been conducted to evaluate the effects of the combination medicine. The evidence from these trials assesses the medicine's impact on reducing cholesterol levels and the observed cardiovascular outcomes in the patient populations studied.

Q: Does Инеджи interact with common over-the-counter pain relievers?

A: The official documentation lists numerous known drug interactions, particularly with medicines that may increase the risk of muscle toxicity. Since the official documentation does not specifically address every common over-the-counter medicine, official documentation states that consulting a healthcare provider before combining with any concomitant medicines is necessary.

Q: Is it normal to feel a bit nauseous when first starting Инеджи?

A: Nausea has been reported in post-marketing experience for the ezetimibe component of the medicine. Other digestive symptoms, such as diarrhea and abdominal pain, have also been reported in clinical trials and post-marketing reports.

Q: How long does the body take to get rid of Инеджи after the last dose?

A: The two components of the medicine are cleared from the body at different speeds. The ezetimibe component (plus its active form) has a long half-life of about 22 hours. In contrast, the simvastatin component and its active form are cleared rapidly from the plasma.

Q: Can older adults use Инеджи, or is there a specific age limit?

A: Clinical studies included patients aged 65 and older, and generally, the effects and safety profile were similar to those in younger patients. However, official documents note that older adults may have an increased risk for myopathy (a muscle issue), and considerations for this population are included in the regulatory documentation.

Q: What kind of studies support the use of Инеджи?

A: The use of the medicine is supported by various clinical studies, including double-blind, placebo-controlled trials and long-term trials. These studies primarily evaluate the drug's effectiveness in reducing LDL-C and other lipid parameters.

Q: Is Инеджи known to cause skin reactions or rashes?

A: Hypersensitivity reactions have been reported in the post-marketing experience for the ezetimibe component. These reactions may include skin rash, urticaria (hives), and angioedema (swelling).

Q: What is the risk of Инеджи causing liver issues?

A: The medicine can cause elevated liver enzymes, and these levels are typically monitored during treatment. Regulatory documents state it is contraindicated (should not be used) by patients with active liver disease or unexplained, persistent enzyme elevations.

Q: Does alcohol change the way Инеджи works in the body?

A: Official documents recommend limiting or avoiding substantial quantities of alcohol when taking this medicine. Excessive alcohol consumption, combined with the simvastatin component's potential for liver effects, may increase the overall risk of liver damage.

Q: What should I do if a side effect of Инеджи seems concerning?

A: Official regulatory guidance describes symptoms that should be promptly reported, such as unexplained muscle pain, weakness, or tenderness, especially if accompanied by fever or general discomfort. These symptoms may be signs of a serious muscle condition.

Q: Can Инеджи be used during pregnancy, according to official documents?

A: According to official regulatory documents, the medicine is contraindicated (not permitted) for use in women who are pregnant or who may become pregnant. This is based on the potential for the medicine to cause harm to the developing fetus.

Q: What information is available regarding the use of Инеджи while breastfeeding?

A: Official information advises that nursing mothers should not breastfeed while using this medicine. This caution is based on the potential for components to be passed into breast milk, which may lead to a risk of serious adverse reactions in the nursing infant.

Q: Does Инеджи have a 'black box warning' or similar important safety statement?

A: The FDA label for this fixed-dose combination drug does not feature a Boxed Warning (sometimes called a 'black box'). However, the official documents do contain several serious Warnings and Precautions, particularly concerning the risks of muscle toxicity (myopathy/rhabdomyolysis) and potential liver dysfunction.

Q: Is there any research looking at how Инеджи affects mood?

A: Official post-marketing experience reports for the ezetimibe component have included instances of depression.

Q: Does Инеджи affect the results of common lab tests?

A: Yes, regulatory documents indicate that the medicine can affect certain lab test results. Specifically, it may cause elevations in serum transaminases (liver enzymes) and creatine kinase (CK) levels. These are laboratory markers monitored during treatment to assess for liver and muscle safety.

Q: How is the research evidence for Инеджи usually summarized by authorities?

A: Authorities summarize the evidence from clinical trials by focusing on the drug’s observed effectiveness in lowering LDL-C and other fats in the blood, and its overall safety profile in the studied patient groups.

Q: Can Инеджи affect a person's ability to drive or operate machinery?

A: Adverse reactions like dizziness and headache are reported in the official information. Because these reactions could potentially impair certain functions, the official documentation states that patients should be aware of how the medicine affects them before engaging in activities like driving or operating complex machinery.

Q: What are the storage guidelines for Инеджи?

A: Official instructions indicate the medicine should be stored at controlled room temperature, which is generally between 20 C and 25 C (68 F and 77 F). The most specific storage instructions are found on the container label.

Q: Is it possible to be allergic to any ingredients in Инеджи?

A: Official documents list the medicine as contraindicated (should not be used) in anyone who has a known hypersensitivity, or allergic reaction, to any component of the drug.

Q: Are there any specific lifestyle changes that are often studied alongside Инеджи use?

A: The official indication states that the medicine is used as an adjunct to diet. This information highlights the importance of dietary changes and measures alongside the medicinal treatment for reducing high cholesterol.

Q: What is the time frame for expecting the full effect of Инеджи?

A: Maximum effectiveness in reducing bad cholesterol (LDL-C) is typically reached around four weeks after treatment begins. Official guidelines suggest monitoring lipid levels (blood fats) within 4 to 12 weeks after a dose change to track progress.

Q: Do people typically use Инеджи for a short time or long term?

A: The medicine is generally intended for long-term use as part of a strategy to manage chronic conditions like high cholesterol. This is supported by the fact that the medicine has been evaluated in long-term clinical trials.

Q: What are the official sources saying about the safety profile of Инеджи?

A: Official sources, such as the FDA and EMA labels, cover the safety profile through sections dedicated to contraindications (who should not use it), warnings about serious risks like muscle toxicity (myopathy), and adverse reactions seen in trials.

Q: What conditions make a person ineligible to use Инеджи?

A: Regulatory documents specify several conditions that make a person ineligible (contraindicated) for the medicine. These include a known allergy to any part of the drug, active liver disease, unexplained persistent elevations in liver enzymes, and for women, being pregnant or breastfeeding.

Q: If a person has kidney issues, is Инеджи still an option?

A: Official documents indicate that caution is advised, and dosage adjustments may be necessary for patients with severe kidney (renal) issues. Kidney impairment is noted as a factor that can potentially increase the risk of muscle-related problems, such as myopathy.

Q: Are there differences in how men and women respond to Инеджи based on studies?

A: Although overall efficacy is similar between genders, official warnings identify the female gender as a predisposing factor for an increased risk of myopathy and rhabdomyolysis. These are serious muscle-related conditions associated with the simvastatin component of the drug.

Q: Can Инеджи be taken with common cold and flu medicines?

A: The official interaction data highlights specific drug types, particularly those that can increase the risk of muscle toxicity. Since the label does not cover every cold and flu medicine, official patient guidance emphasizes the need to consult a healthcare provider before taking any new over-the-counter medications.

Q: Do official documents mention any potential for long-term health risks from Инеджи?

A: Yes, official warnings address potential risks that may occur during extended use, such as the risk of myopathy (a muscle disease) and the potential for persistent elevations in liver enzymes. Monitoring is typically required during long-term treatment.

Q: What is meant by the drug's 'mechanism of action'?

A: The 'mechanism of action' describes how the drug works to lower cholesterol. The two components work differently: ezetimibe blocks the absorption of cholesterol in the small intestine, and simvastatin blocks an enzyme in the liver that is needed to make cholesterol.

How to Store and Dispose of INEGY (Ezetimibe/Simvastatin)

Official regulatory information specifies strict conditions for storing and disposing of INEGY tablets to maintain stability and ensure safety.

---

Storage Requirements

• Temperature Limit: The medicine must be stored at a temperature not exceeding 30°C.
• Environmental Protection: Keep the tablets in their original container to protect them from moisture and light.
• Child Safety: INEGY must be stored out of the sight and reach of children.
• Stability: Do not use the tablets after the expiry date (EXP) stated on the packaging.

---

Disposal Instructions

Unused or expired medicinal product and waste material must be disposed of in accordance with local requirements. The product should not be discarded into wastewater or household trash unless specifically authorized by local authorities.